Go Pro
OTCMKTS:EKTAY

Elekta Q1 2026 Earnings Report

Elekta logo
$5.57 0.00 (0.00%)
As of 08/17/2026 03:28 PM Eastern

Elekta EPS Results

Actual EPS
$0.03
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Elekta Revenue Results

Actual Revenue
$379.64 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Elekta Announcement Details

Quarter
Q1 2026
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Elekta's next earnings date is estimated for Thursday, August 27, 2026, based on past reporting schedules.

Conference Call Resources

Elekta Earnings Headlines

Elekta (OTCMKTS:EKTAY) Sees Strong Trading Volume - Still a Buy?
The cat is out the bag
Almost 80,000 tech jobs vanished in the first three months of 2026. Meta cut 14,000 roles, Microsoft offered separation packages to 8,500 workers, and Oracle is reportedly eliminating up to 30,000 positions. Goldman Sachs estimates 12,400 Americans are being financially displaced every single day. Analyst Porter Stansberry says the real driver runs deeper than AI - and two Nobel Prize winners have issued the same warning. He calls it the Final Displacement, and he's releasing a full investigation with specific companies to buy and sell before the next wave hits.tc pixel
See More Elekta Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Elekta? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Elekta and other key companies, straight to your email.

About Elekta

Elekta (OTCMKTS:EKTAY) is a global medical technology company specializing in the development, manufacture and support of precision radiation therapy and radiosurgery equipment. Its products and services aim to improve patient outcomes in oncology and neurosurgery by combining advanced hardware, software and clinical workflow solutions. Elekta’s offerings are designed to address a broad range of cancer types and brain disorders through targeted, image-guided treatments.

The company’s core product portfolio includes linear accelerators for external beam radiation therapy, stereotactic radiosurgery systems such as the renowned Gamma Knife platform, and brachytherapy solutions for internal radiation treatment. Elekta also provides oncology information systems and treatment planning software that enable seamless integration of imaging, planning and delivery for multidisciplinary clinical teams. In addition, the company offers comprehensive service and support programs, clinical training and educational resources to ensure optimal system performance and professional development for its customers.

Founded in 1972 by Swedish neurosurgeon Lars Leksell, Elekta pioneered stereotactic radiosurgery and has since grown into a worldwide provider of precision cancer care technologies. Headquartered in Stockholm, Sweden, the company serves hospitals, cancer centers and clinics across Europe, North America, Asia-Pacific, Latin America, the Middle East and Africa. Elekta maintains regional offices and service centers to support installation, maintenance and training programs in key markets around the globe.

Guided by a leadership team of experienced executives and a board of directors with deep expertise in healthcare technology, Elekta continues to invest in research and development to advance treatment efficacy and patient quality of life. The company collaborates with academic institutions, clinical partners and industry stakeholders to drive innovation in radiotherapy and radiosurgery and to shape the future of precision cancer care.

View Elekta Profile